ARWR insider trading
NasdaqGS HealthcareARROWHEAD PHARMACEUTICALS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About ARROWHEAD PHARMACEUTICALS, INC.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Company website: arrowheadpharma.com
ARWR insider activity at a glance
FilingIQ has scored 632 insider transactions for ARWR since Oct 9, 2013. The most recent filing in our index is dated May 12, 2026.
Across the full history, 16 open-market purchases
and 393 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ARWR insider trades is 60.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ARWR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding ARWR
Frequently asked
- How many insider trades does FilingIQ track for ARWR?
- FilingIQ tracks 632 Form 4 insider transactions for ARWR (ARROWHEAD PHARMACEUTICALS, INC.), covering filings from Oct 9, 2013 onwards. 6 of those were filed in the last 90 days.
- Are ARWR insiders net buyers or net sellers?
- Across the full Form 4 history for ARWR, 16 transactions (3%) were open-market purchases and 393 (62%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ARWR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ARWR in?
- ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.93B.
Methodology & sources
Every ARWR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.